194 related articles for article (PubMed ID: 36158143)
21. Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets.
Barrera-Chimal J; Jaisser F
Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():16-31. PubMed ID: 32267077
[TBL] [Abstract][Full Text] [Related]
22. Transforming Diabetes Care: The Molecular Pathways through Which GLP1-RAs Impact the Kidneys in Diabetic Kidney Disease.
Rroji M; Spasovski G
Biomedicines; 2024 Mar; 12(3):. PubMed ID: 38540270
[TBL] [Abstract][Full Text] [Related]
23. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.
DeFronzo RA; Bakris GL
Diabetes Obes Metab; 2022 Jul; 24(7):1197-1205. PubMed ID: 35302284
[TBL] [Abstract][Full Text] [Related]
24. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
St Peter WL; Odum LE; Whaley-Connell AT
Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
[TBL] [Abstract][Full Text] [Related]
25. Update of pathophysiology and management of diabetic kidney disease.
Lin YC; Chang YH; Yang SY; Wu KD; Chu TS
J Formos Med Assoc; 2018 Aug; 117(8):662-675. PubMed ID: 29486908
[TBL] [Abstract][Full Text] [Related]
26. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
[TBL] [Abstract][Full Text] [Related]
27. Dipeptidyl peptidase-4 inhibition in chronic kidney disease and potential for protection against diabetes-related renal injury.
Penno G; Garofolo M; Del Prato S
Nutr Metab Cardiovasc Dis; 2016 May; 26(5):361-73. PubMed ID: 27105869
[TBL] [Abstract][Full Text] [Related]
28. Management of Hypertension in Patients With Diabetic Kidney Disease: Summary of the Joint Association of British Clinical Diabetologists and UK Kidney Association (ABCD-UKKA) Guideline 2021.
Banerjee D; Winocour P; Chowdhury TA; De P; Wahba M; Montero R; Fogarty D; Frankel A; Goldet G; Karalliedde J; Mark PB; Patel D; Pokrajac A; Sharif A; Zac-Varghese S; Bain S; Dasgupta I;
Kidney Int Rep; 2022 Apr; 7(4):681-687. PubMed ID: 35497783
[TBL] [Abstract][Full Text] [Related]
29. Association of Glucagon-Like Peptide-1 Receptor Agonist vs Dipeptidyl Peptidase-4 Inhibitor Use With Mortality Among Patients With Type 2 Diabetes and Advanced Chronic Kidney Disease.
Chen JJ; Wu CY; Jenq CC; Lee TH; Tsai CY; Tu HT; Huang YT; Yen CL; Yen TH; Chen YC; Tian YC; Yang CW; Yang HY
JAMA Netw Open; 2022 Mar; 5(3):e221169. PubMed ID: 35254430
[TBL] [Abstract][Full Text] [Related]
30. Diabetic Kidney Disease: Diagnosis, Treatment, and Prevention.
McGrath K; Edi R
Am Fam Physician; 2019 Jun; 99(12):751-759. PubMed ID: 31194487
[TBL] [Abstract][Full Text] [Related]
31. Non-steroidal mineralocorticoid antagonists: Prospects for renoprotection in diabetic kidney disease.
Al Dhaybi O; Bakris GL
Diabetes Obes Metab; 2020 Apr; 22 Suppl 1():69-76. PubMed ID: 32267074
[TBL] [Abstract][Full Text] [Related]
32. Recent advances in the pharmacotherapeutic management of diabetic kidney disease.
Block TJ; Batu D; Cooper ME
Expert Opin Pharmacother; 2022 May; 23(7):791-803. PubMed ID: 35522659
[TBL] [Abstract][Full Text] [Related]
33. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
Ruilope LM; Agarwal R; Anker SD; Bakris GL; Filippatos G; Nowack C; Kolkhof P; Joseph A; Mentenich N; Pitt B;
Am J Nephrol; 2019; 50(5):345-356. PubMed ID: 31665733
[TBL] [Abstract][Full Text] [Related]
34. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
Alicic RZ; Johnson EJ; Tuttle KR
Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460
[TBL] [Abstract][Full Text] [Related]
35. Diabetic Kidney Disease: Challenges, Advances, and Opportunities.
Chen Y; Lee K; Ni Z; He JC
Kidney Dis (Basel); 2020 Jul; 6(4):215-225. PubMed ID: 32903946
[TBL] [Abstract][Full Text] [Related]
36. The Pillars for Renal Disease Treatment in Patients with Type 2 Diabetes.
Kearney J; Gnudi L
Pharmaceutics; 2023 Apr; 15(5):. PubMed ID: 37242585
[TBL] [Abstract][Full Text] [Related]
37. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials.
Chaudhuri A; Ghanim H; Arora P
Diabetes Obes Metab; 2022 Mar; 24(3):365-376. PubMed ID: 34779091
[TBL] [Abstract][Full Text] [Related]
38. The kidney and cardiovascular outcome trials.
Bloomgarden Z
J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
[TBL] [Abstract][Full Text] [Related]
39. Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials.
Giugliano D; De Nicola L; Maiorino MI; Bellastella G; Esposito K
Diabetes Obes Metab; 2019 Aug; 21(8):1790-1800. PubMed ID: 30969018
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]